Skip to content
Snap Inc's (NYSE:SNAP social media platform, Snapchat, brought a refreshing change to social networks when it first launched, but the landscape is more competitive now than ever before as other platforms adopted the company's story feature. Snap reports second-quarter earnings on Tuesday after the market closes. EPS and sales numbers are always important, with consensus estimates looking for a loss of 10 cents per share and $433.11 million sales, but each company has its own specific updates to look for. Here are four things to watch in Snap's earnings report.Daily Active Users: One of the most important metrics of social media platforms to look out for is its Daily Active Users (DAUs). The more users a platform has, the more popular it is and therefore it will earn more revenue from advertisers."We estimate that Snap will add 10MM Net New DAUs in Q2 vs. 11MM in Q1 and 13MM in Q2:19,"...
Congress has authorized $3.6 trillion in stimulus money to help offset the punishing cost of the lockdowns and business closures caused by the coronavirus pandemic. Congress is now developing another massive round of stimulus spending that will probably top $1 trillion. Yahoo Finance's Rick Newman joins The Final Round to discuss. ...
Discover how low viscosity engine oils can improve your fleet’s overall fuel economy and productivity. ...
Tesla shares will be a must-watch stock when the electric vehicle maker reports earnings this Wednesday after the market close....
The COVID-19 pandemic has translated into staggering gains for some biotech stocksthis year, rendering valuations unattractive even after the positive financial impact of the viral outbreak is taken into consideration. Valuation Bubble In Play: It's a no-brainer that some biotechs that are working on coronavirus vaccines or treatments are making heady gains.Novavax, Inc. (NASDAQ: NVAX), Moderna Inc (NASDAQ: MRNA) and Inovio Pharmaceuticals Inc (NASDAQ: INO) are among the COVID-19-levered biotechs that are riding the wave of pandemic news. Other stocks like Zoom Video Communications Inc (NASDAQ: ZM) and Teladoc Health Inc (NYSE: TDOC) are capitalizing on the restrictions put in place to contain the spread of the virus. Data Source: Yahoo Finance and YChartsNovavax Gets Fresh Lease of Life: Novavax on the brink early in 2019 after its respiratory syncytial virus vaccine candidate flunked a late-stage study.The company effected a 1-for-20 reverse split in May 2019 to give a decent look...
